P38Alpha as a Therapeutic Target in Bladder Carcinoma
AssigneesInstitut Curie, Centre National De La Recherche Scientifique, Assistance Publique-Hopitaux de Paris, Universite Paris 12
InventorsIsabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors.
Claims20
1-13. (canceled)
A method for treating a subject suffering of a bladder tumor or carcinoma comprising administering a therapeutically efficient amount of a p38α inhibitor.
A method for selecting a subject suffering of a bladder carcinoma or tumor suitable to be treated by a p38α inhibitor comprising, determining in a sample from a subject if FGFR3 or RAS has a mutation, and selecting the subject for treatment with a p38α inhibitor if said subject has a mutated FGFR3 or RAS.
Dependencies are inferred from the claim text.